Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9545405 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(11 years from now) | |
US9035074 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9549929 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 14, 2027 |
Drugs and Companies using ABROCITINIB ingredient
NCE-1 date: January, 2026
Market Authorisation Date: 14 January, 2022
Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8148401 | PFIZER | Benzimidazole derivatives |
Jan, 2031
(8 years from now) | |
US10414748 | PFIZER | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Apr, 2036
(13 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8431597 | PFIZER | Benzimidazole derivatives |
Jun, 2028
(5 years from now) | |
US11168066 | PFIZER | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Apr, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 21, 2023 |
Orphan Drug Exclusivity (ODE) | Nov 21, 2025 |
Drugs and Companies using GLASDEGIB MALEATE ingredient
NCE-1 date: November, 2022
Market Authorisation Date: 21 November, 2018
Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6936612 | PFIZER | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
Jan, 2023
(11 days ago) | |
US7208489 | PFIZER | 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones |
Jan, 2023
(11 days ago) | |
USRE47739 | PFIZER | 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones |
Mar, 2027
(4 years from now) | |
US10723730 | PFIZER | Solid forms of a selective CDK4/6 inhibitor |
Feb, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7456168 | PFIZER | 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones |
Jan, 2023
(11 days ago) | |
US11065250 | PFIZER | Solid dosage forms of palbociclib |
May, 2036
(13 years from now) |
Drugs and Companies using PALBOCICLIB ingredient
Market Authorisation Date: 01 November, 2019
Treatment: Palbociclib for hr-pos. her2-neg. advanced or metastatic breast cancer in combo with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or men, or with fulvestrant in pts with disease progression after endocrine therapy
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8680111 | PFIZER | Macrocyclic derivatives for the treatment of diseases |
Mar, 2033
(10 years from now) | |
US10420749 | PFIZER | Crystalline form of lorlatinib free base |
Jul, 2036
(13 years from now) | |
US11299500 | PFIZER | Crystalline form of lorlatinib free base hydrate |
Oct, 2038
(15 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11020376 | PFIZER | Crystalline form of lorlatinib free base |
Jul, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 2, 2023 |
Orphan Drug Exclusivity (ODE) | Mar 3, 2028 |
New Indication (I) | Mar 3, 2024 |
Drugs and Companies using LORLATINIB ingredient
NCE-1 date: November, 2022
Market Authorisation Date: 02 November, 2018
Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer, progressed on: crizotinib + at least 1 other alk inhibitor for metastatic disease; Or alectinib, or ceritinib as first alk inhibitor for metastatic disease.; Treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive as detected by an fda-approved test
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8420650 | PFIZER | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
Jul, 2029
(6 years from now) | |
US8012976 | PFIZER | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
Oct, 2029
(6 years from now) | |
US10189837 | PFIZER | Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt |
Oct, 2031
(8 years from now) | |
US8735392 | PFIZER | Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt |
Oct, 2031
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9820985 | PFIZER | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
Jul, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Oct 16, 2023 |
Drugs and Companies using TALAZOPARIB TOSYLATE ingredient
NCE-1 date: October, 2022
Market Authorisation Date: 16 October, 2018
Treatment: Treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (brca)-mutated (gbrcam) human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6858650 | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jul, 2022
(6 months ago) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6858650
(Pediatric) | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jan, 2023
(24 days ago) | |
US7807715 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(4 years from now) | |
US8501723 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(4 years from now) | |
US8088398 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(4 years from now) | |
US8088398
(Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(4 years from now) | |
US8501723
(Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(4 years from now) | |
US7807715
(Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Jun 17, 2024 |
Pediatric Exclusivity (PED) | Dec 17, 2024 |
Drugs and Companies using FESOTERODINE FUMARATE ingredient
Market Authorisation Date: 31 October, 2008
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8685443 | PFIZER | Sequestering subunit and related compositions and methods |
Jul, 2025
(2 years from now) | |
US7815934 | PFIZER | Sequestering subunit and related compositions and methods |
Dec, 2027
(4 years from now) |
Drugs and Companies using NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 August, 2016
Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7772243 | PFIZER | 4-phenylamino-quinazolin-6-yl-amides |
Aug, 2028
(5 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8623883 | PFIZER | 4-phenylamino-quinazolin-6-yl-amides |
May, 2025
(2 years from now) | |
US10596162 | PFIZER | Method for treating gefitinib resistant cancer |
Feb, 2026
(3 years from now) | |
US10603314 | PFIZER | Method for treating gefitinib resistant cancer |
Feb, 2026
(3 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 27, 2025 |
New Chemical Entity Exclusivity (NCE) | Sep 27, 2023 |
Drugs and Companies using DACOMITINIB ingredient
NCE-1 date: September, 2022
Market Authorisation Date: 27 September, 2018
Treatment: First-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test; Administering daily a unit dosage of an irreversible egfr inhibitor covalently binding as claimed for 1st line treatment of gefitinib or erlotinib resistant metastatic nsclc with egfr exon 19 deletion or exon 21 l858r substitution with t790m mutation; Administering daily a unit dosage of an irreversible egfr inhibitor covalently binding as claimed for 1st line treatment of gefitinib of erlotinib resistant metastatic nsclc with egfr exon 19 deletion or exon 21 l858r substitution
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(2 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Sep 25, 2023 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
Market Authorisation Date: 25 September, 2020
Treatment: NA
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6965027 | PFIZER | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(a month from now) | |
USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11253523 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(11 years from now) | |
US10639309 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(11 years from now) | |
US9937181 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Dec 14, 2024 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
Market Authorisation Date: 23 February, 2016
Treatment: A method of treating ankylosing spondylitis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-43, 45, 47, 49, 50, 54, 59, 63, 68-71, 73, 77, 82-84, and 87-98; A method of treating psoriatic arthritis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-44, 46, 48, 50, 53, 59, 62, 68-71, 73, 76, 82-84, and 87-98; A method of treating rheumatoid arthritis by administering the formulation of tofacitinib of claims 1, 2, 8, 9, 15-21, 27-31, 34-43, 50, 51, 59, 60, 68-71, 73, 74, 82-84 and 87-98; A method of treating ulcerative colitis, by administering the formulation of tofacitinib of claims 1, 3, 8, 10, 15-20, 22, 27-31, 34-43, 50, 52, 59, 61, 68-71, 73, 75, 82-84 and 87-98
Dosage: TABLET, EXTENDED RELEASE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic